BR112016026422A2 - solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson - Google Patents

solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson

Info

Publication number
BR112016026422A2
BR112016026422A2 BR112016026422A BR112016026422A BR112016026422A2 BR 112016026422 A2 BR112016026422 A2 BR 112016026422A2 BR 112016026422 A BR112016026422 A BR 112016026422A BR 112016026422 A BR112016026422 A BR 112016026422A BR 112016026422 A2 BR112016026422 A2 BR 112016026422A2
Authority
BR
Brazil
Prior art keywords
dopamine
parkinson
disease
treatment
pharmaceutical solution
Prior art date
Application number
BR112016026422A
Other languages
English (en)
Inventor
Moreau Caroline
Laloux Charlotte
Devos David
Devedjian Jean-Christophe
Original Assignee
Centre Hospitalier Regional Et Univ De Lille Chru
Univ Lille Ii Droit & Sante
Univ Du Littoral Cote Dopale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Lille Chru, Univ Lille Ii Droit & Sante, Univ Du Littoral Cote Dopale filed Critical Centre Hospitalier Regional Et Univ De Lille Chru
Publication of BR112016026422A2 publication Critical patent/BR112016026422A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a uma solução farmacêutica que compreende pelo menos dopamina para uso no tratamento da doença de parkinson, em que a referida solução farmacêutica é mantida sob condições anaeróbicas desde a sua formulação até a sua administração
BR112016026422A 2014-05-13 2015-05-12 solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson BR112016026422A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1454254 2014-05-13
EP15305352 2015-03-09
PCT/EP2015/060511 WO2015173258A1 (en) 2014-05-13 2015-05-12 Pharmaceutical solution comprising dopamine for use in treating parkinson's disease

Publications (1)

Publication Number Publication Date
BR112016026422A2 true BR112016026422A2 (pt) 2017-12-05

Family

ID=53059131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016026422A BR112016026422A2 (pt) 2014-05-13 2015-05-12 solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson

Country Status (15)

Country Link
US (2) US10105326B2 (pt)
EP (2) EP3142651B1 (pt)
JP (2) JP6496815B2 (pt)
AU (2) AU2015260953B2 (pt)
BR (1) BR112016026422A2 (pt)
CA (1) CA2947474C (pt)
DK (2) DK3142651T3 (pt)
ES (2) ES2714726T3 (pt)
FI (1) FI3453388T3 (pt)
HU (1) HUE042456T2 (pt)
IL (2) IL274203B2 (pt)
PL (1) PL3142651T3 (pt)
PT (1) PT3142651T (pt)
TR (1) TR201903234T4 (pt)
WO (1) WO2015173258A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876697A (zh) * 2021-09-26 2022-01-04 武汉久安药业有限公司 一种盐酸多巴胺的注射液及其制备工艺
WO2024056749A1 (en) 2022-09-14 2024-03-21 Inbrain Pharma Pharmaceutical injectable solution comprising dopamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR114796A (fr) 1876-10-03 1876-12-02 Demouchy A M Manches de pelles courbes
JPH11128314A (ja) * 1997-10-28 1999-05-18 Kyowa Hakko Kogyo Co Ltd シリンジ製剤
FR2832063B1 (fr) * 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
JP2008068122A (ja) * 2007-11-01 2008-03-27 Kyowa Hakko Kogyo Co Ltd シリンジ製剤
JP2012001493A (ja) * 2010-06-17 2012-01-05 Terumo Corp 塩酸リトドリン注射製剤
MX2012012559A (es) * 2012-10-29 2014-04-28 Patricia Vergara Aragon Composicion de tio2/dopamina implantada en el cerebro de la rata para el tratamiento del hemiparkinsonismo.

Also Published As

Publication number Publication date
US10105326B2 (en) 2018-10-23
JP2019085421A (ja) 2019-06-06
PT3142651T (pt) 2019-03-21
ES2714726T3 (es) 2019-05-29
AU2020203126B2 (en) 2021-07-15
CA2947474C (en) 2022-05-17
FI3453388T3 (fi) 2023-05-09
WO2015173258A1 (en) 2015-11-19
JP2017515905A (ja) 2017-06-15
IL248672B (en) 2020-05-31
EP3453388A1 (en) 2019-03-13
IL274203B1 (en) 2023-08-01
CA2947474A1 (en) 2015-11-19
AU2015260953B2 (en) 2020-02-27
IL274203B2 (en) 2023-12-01
DK3142651T3 (en) 2019-03-25
EP3453388B1 (en) 2023-02-15
HUE042456T2 (hu) 2019-06-28
AU2020203126A1 (en) 2020-06-04
ES2943567T3 (es) 2023-06-14
DK3453388T3 (da) 2023-04-24
NZ725828A (en) 2023-10-27
US20190022034A1 (en) 2019-01-24
US20170151193A1 (en) 2017-06-01
EP3142651A1 (en) 2017-03-22
EP3142651B1 (en) 2018-12-12
IL274203A (en) 2020-06-30
JP7475113B2 (ja) 2024-04-26
TR201903234T4 (tr) 2019-03-21
AU2015260953A1 (en) 2016-11-17
IL248672A0 (en) 2017-01-31
JP6496815B2 (ja) 2019-04-10
PL3142651T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201790785A1 (ru) Производные тетрагидроизохинолина
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]